Dacomitinib resistance time and response strategies

Dacomitinib (Dacomitinib), as a targeted therapy for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), has shown significant efficacy in clinical applications. However, similar to many targeted drugs, dacomitinib may also encounter resistance problems during treatment. The time of emergence varies depending on individual patients, and usually appears within a treatment cycle of months to years.

According to statistics, the median progression-free survival time (PFS) of patients treated with dacomitinib is approximately 12-15 months, which means that within this time period, about half of the patients may encounter drug resistance. However, it is worth noting that this is only an average data, and the actual resistance time varies depending on the specific situation of the patient. Some patients may develop resistance in just a few months, while others may not face the problem until a year or more after treatment.

The development of drug resistance is mainly divided into two categories: primary resistance and acquired resistance. Primary resistance refers to patients who are insensitive to dacomitinib (dacomitinib) from the beginning of treatment, which may be due to the presence of other genetic mutations in tumor cells or the activation of alternative signaling pathways. Acquired drug resistance gradually appears after a period of treatment, often due to new gene mutations in tumor cells, such as secondary mutations of EGFR (such as T790M mutations) or other related genes (such as MET, HER2, etc.) mutations or amplifications, resulting in tumor cells being able to circumvent the inhibitory effect of dacomitinib (dacomitinib) .

In order to effectively deal with the challenge of drug resistance, a variety of strategies have been adopted clinically. The first is to implement regular monitoring. Through imaging examinations and biomarker testing, signs of drug resistance can be detected early and treatment plans can be adjusted in a timely manner. Secondly, drug combination strategies are recommended to combine dacomitinib with other drugs in order to delay the development of drug resistance. Finally, for patients who have developed drug resistance, doctors will choose other targeted drugs or chemotherapy regimens for treatment based on the specific resistance mechanism. For example, for patients with T790M mutation, third-generation EGFR such as Osimertinib can be considered.inhibitors to continue to effectively control the disease.